NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Autoimmunity BioSolutions

Autoimmunity BioSolutions

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.abstherapeutics.com/

Last Round

Seed

May 6, 2026

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Autoimmunity BioSolutions is a biotechnology company developing a next-generation, immuno-corrective antibody therapy for the treatment of autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

monoclonal antibodiesautoimmune disease therapymAbsantibody therapeuticsimmune tolerancebiologicspreclinical biotechdrug discoverybiopharmaT cell modulationanti-CD6drug licensingpharma partnershipsantisense oligonucleotideASONIH SBIR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Autoimmunity BioSolutions Comparables

Compare Autoimmunity BioSolutions with similar companies based on industry and business-model similarity.

Autoimmunity BioSolutions comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AbolerIS Pharma
78%
Anokion
76%
Equillium Inc.
76%

Autoimmunity BioSolutions Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 6, 2026

Key People

Founding team and executive leadership

Thomas Forest Farb-Horch

CEO, President And Board Member At Thrive Bioscience, Inc.

Executive Team

Autoimmunity BioSolutions Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 6, 2026

    Raised $3.2M in Seed funding.

  • Feb 17, 2026

    Grew 250% QoQ from 2 to 7 employees.

Autoimmunity BioSolutions Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Autoimmunity BioSolutions Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Autoimmunity BioSolutions's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range7
Year Founded2016
Last FundingMay 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.